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Abstract: Background: A new trend among users of new psychoactive substances’ the consumption 
of “herbal highs”: plant parts containing psychoactive substances. Most of the substances extracted 
from herbs, in old centuries were at the centre of religious ceremonies of ancient civilizations. 
Currently, these herbal products are mainly sold by internet web sites and easily obtained since some 
of them have no legal restriction. 
Objective: We reviewed psychoactive effects and neuropharmacology of the most used “herbal highs” 
with characterized active principles, with studies reporting mechanisms of action, pharmacological 
and subjective effects, eventual secondary effects including intoxications and/or fatalities 
Method: The PubMed database was searched using the following key.words: herbal highs, Argyreia 
nervosa, Ipomoea violacea and Rivea corymbosa; Catha edulis; Datura stramonium; Piper 
methysticum; Mitragyna speciosa. 
Results: Psychoactive plants here reviewed have been known and used from ancient times, even if for 
some of them limited information still exist regarding subjective and neuropharmacological effects 
and consequent eventual toxicity when plants are used alone or in combination with “classical” drugs 
of abuse. 
Conclusion: Some “herbal highs” should be classified as harmful drugs since chronic administration 
has been linked with addiction and cognitive impairment; for some others taking into consideration 
only the recent trends of abuse, studies investigating these aspects are lacking. 
Keywords: Herbal highs, plant material, psychoactive herbal products, neuropharmacology. 
INTRODUCTION 
 Among New Psychoactive Substances (NPS), a new 
trend among users includes the consumption of “herbal 
highs”: plant parts containing psychoactive substances [1]. 
These herbal products, mainly coming from South America 
or Asia where this material has traditionally been used since 
ancient times, recently increased their popularity. The 
possibility of e-commerce, the popularity through web forum 
of users opened the market to this “natural” (opposite to 
synthetic) option to consume psychoactive compounds. 
Unfortunately, at the moment there are no data about the  
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number of persons consuming herbal highs nor about 
relevance of consumption on the online market or in dark 
market just because information, diffusion and selling are 
made anonymously, by web forums and as mentioned earlier 
mainly by dark internet. What is known by the most recent 
global drug survey is that one out of 10 survey participants 
used “dark net” to buy NPS including herbal highs, that 5% 
respondents did not use any NPS before knowing and using 
this drug supply system and finally that even if classical 
drugs of abuse consumption is still highly prevalent, some 
“herbal highs” use (e.g. Kratom or khat) in the last year was 
reported by about 1% responders [2]. 
 Most of the “herbal highs” have been well known in the 
past centuries and used as sacred substances in traditional 
rites or as medicines by different ancient cultures [3]. 
Actually herbal highs are perceived as safe products since, as 
above reported, they are “natural” and “biologic”. 
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 Nevertheless, similarly to many synthetic drugs, plant 
and herbal supplements used recreationally can show a broad 
spectrum of euphoric, stimulant, and mainly hallucinogenic 
effects. Even if abuse liability is not a crucial point for these 
products, serious adverse effects can occur after 
consumption, due also to the false perception that these 
products are safe, legal, and organic. 
 Currently, an established definition of herbal highs does 
not exist. In the majority of cases this is intended as a 
synonymous of “legal highs”, which is not. Conversely, the 
pharmacological identity of legal highs often resembles 
substances legally controlled (i.e. amphetamines, cannabis). 
However legal highs can be legally consumed and obtained 
from online vendors or in so-called “head shops” [4]. 
 Nor herbal highs can be considered as “spice drugs” 
defined as herbal blends containing synthetic cannabinoids 
surreptitiously added to obtain psychotropic effects [5]. The 
plant can contains one or more active component that, per se, 
undergoes to drug law policy. However, it can occur that the 
plant or part of it are not included, and can be considered 
legal. There are several web sites where it is possible obtain 
herbal products anonymously and with a very low control 
level. 
 In this review, as” herbal highs” we considered those 
plants or part of them containing psychoactive active 
principles (alkaloids, terpenes, etc), which are used as fresh 
or dry material to be chewed, smoked, drunk as a tea, or as a 
juice or beverage in the aim of obtaining psychotropic 
effects. 
 Among the elevated number of vegetal material with the 
above reported characteristics, we chose to review not only 
the ones with characterized active principles, with studies 
reporting mechanisms of action, pharmacological and 
subjective effects, eventual secondary effects including 
intoxications and/or fatalities, but also those which acquired 
more interest among users and result, by anecdotal information, 
the most used. 
 Specifically, we focused on the psychoactive effects and 
neuropharmacology of: Ayahuasca; Argyreia nervosa, 
Ipomea violacea and Rivea corymbosa, Catha edulis, Datura 
stramonium, Piper methysticum, Mitragyna speciosa, 
Hallucinogenic cacti from Trichocereus family, Salvia 
divinorum and Tabernanthe iboga. 
METHODS/LITERATURE SEARCH STRATEGY 
 Relevant scientific articles were searched from Medline, 
Cochrane Central, Scopus, Web of Science, Science Direct, 
EMBASE and Google Scholar, up to March 2016 using the 
following keywords: herbal highs, Ayahuasca; Argyreia 
nervosa, Ipomea violacea and Rivea corymbosa; Catha 
edulis; Datura stramonium; Piper methysticum; Mitragyna 
speciosa; Trichocereus cacti; Salvia divinorum and 
Tabernanthe iboga and the known active principles of  
the above reported plants plus pharmacology, neuro- 
pharmacology and psychoactive effects. Then, the references 
of each found article were revised to find other information 
relative to the searched plant. 
RESULTS 
Ayahuasca: the Magic Drink Made of Banisteriopsis caapi 
and Psychotria viridis 
 Ayahuasca (aka, Huasca, Yagé, Daime, Pharma-huasca, 
The Vine, The Tea, La Purga, vine of the souls) is a 
powerfully psychedelic South American brew, traditionally 
made from Banisteriopsis caapi hallucinogenic vine in the 
Malpighiaceae plant family (which contains β-carboline harmala 
alkaloids: harmine, harmaline and tetrahydroharmine) along 
other medicinal plants, i.e. Psychotria viridis containing the 
hallucinogenic active principle dimethyltryptamine (DMT) 
[6]. Even if the above reported plants are most commonly 
used to prepare the beverage, Mimosa hostilis, Mimosa 
tenuiflora Anadenanthera peregrina: Pilocarpus organensis, 
Acacia obtusifolia are also employed as a font of DMT 
whereas Peganum Harmala and Passiflora or Passion 
flowers as font of harmala alkaloids [6]. 
 In the ancient times, the shamans of the indigenous 
western Amazonian tribes usually took the plant as purgative 
and/or antiparasitic during the religious and healing ceremonies, 
while presently it is a sacred beverage of some religious 
communities in Brazil and North America (Santo Daime) [7]. 
 Ayahuasca is usually prepared by boiling or soaking 
parts of the above reported plants [6]. During the process, 
DMT, which is practically inactive if orally taken, as it is 
broken down by the digestive enzyme monoamine oxidases 
(MAOs) before reaching the central nervous system, became 
active and effective when combined with a β-carbolines 
contained in Banisteriopsis caapi, which are potent MAOs 
inhibitors [8]. 
 Psychedelic effects of Ayahuasca are dose-dependent. 
Their onset takes generally 20-60 minutes after oral intake 
and may last approximately 2-6 hours. They may comprise 
vomiting and/or diarrhoea (which usually accompany the 
‘psychedelic experience’), strong visual effects (e.g., snakes, 
big cats, insectoid aliens, etc.), euphoria, mind-altering 
entheogenic effects [9]. Conversely adverse effects include 
untoward effects include fear, paranoia, disequilibrium, 
coma up to death [10]. 
 Although the endogenous presence of DMT in brain 
tissue is recognized, its biological function remains a 
mystery [11]. It has been hypothesized that DMT may have a 
role, not yet been established, in normal physiology and/or 
psychopathology [11]. At central nervous system receptor 
level, DMT interacts with serotonergic neurotransmission due 
to its structural similarity with the endogenous neurotransmitter 
serotonin (5-hydroxytryptamine; 5-HT) Furthermore, DMT 
is an agonist for 5-HT2A and 5-HT1A receptors sites [12]. 
Furthermore, similar to the classical psychedelics, i.e, 
mescaline, LSD, psilocybin, DMT presents agonist activity 
for the 5-HT2Areceptor [12]. It has been shown that 
psychedelic 5-HT2 agonists stimulate the expression of 
genes encoding transcription factors, such as egr-1 and egr-2 
[13]. These transcription factors have been implicated in 
synaptic plasticity and in some aspects of reasoning, such as 
memory and attention [14-16]. DMT also interacts with the 
intracellular sigma-1 receptor promoting neural plasticity 
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through dendritic spine formation, trace amine associated 
receptor and vesicle monoamine and serotonin transporters 
[17-19]. 
 It has been postulated that whereas DMT action on 5-
HT2 receptors is responsible for acute effects induced by 
Ayahuasca, changes in transcription factors may affect 
changes in personality observed in long-term users of 
Ayahuasca [20]. It was shown that repeated exposure to 
Ayahuasca could cause structural differences in the posterior 
cingulate cortex, and consequently a shift in attitudes and 
interests towards less materialistic values and superior open-
mindedness. It is also plausible that the antidepressant 
effects recently reported for Ayahuasca are partly mediated 
by agonism on sigma-1 receptor, an effected shared with 
some selective serotonin reuptake inhibitors, such as 
fluvoxamine [21]. Finally, Ayahuasca subjective effects are 
also due to the pharmacological actins of the β-carbolines, 
contained in Banisteriopsis caapi. These substances not only 
inhibit MAOs enzymes, but also act as the inhibitors of the 
serotonin transporter [22]. 
Argyreia nervosa, Ipomea violacea and Rivea corymbosa: 
The Plants with Hallucinogenic Seeds 
 Argyreia nervosa (also called Hawaiian Baby Woodrose, 
Adhoguda or Vidhara, Elephant Creeper and Woolly 
Morning Glory) is a perennial climbing vine with pink 
flowers, native to the Indian subcontinent and introduced to 
numerous areas worldwide, including, Africa, Subtropical 
America, and Europe. The two botanical varieties are 
Nervosa and Speciosa; for both, the whole plant has been 
used in traditional ayurvedic medicine [23]. Leaves of the 
plant have antibacterial and antimicrobial activity, roots are 
used in rheumatism, gonorrhea, chronic ulcer and diseases of 
nervous system. The plant is also used as a tonic, diuretic 
and aphrodisiac, and has been shown to have hypoglycemic, 
immunomodulatory, hepatoprotective, anti-inflammatory, 
and analgesic activities [24, 25]. 
 Ipomoea violacea (Morning glory, Heavenly blue, Pearly 
Gates, Flying Saucers, Blue Star, Wedding Bells, Summer 
Skies, or Badoh negro) with purple flowers is also perennial 
climbing vine coming from South America. It has been 
described that the plant seeds (named ololiuqui and tlitliltzin) 
have been used in divinatory ceremonies because of their 
hallucinogenic properties by the native Americans [26]. 
 Rivea corymbosa (Christmasvine, Christmaspops, and 
snakeplant) is a perennial climbing vine too with white 
flowers, native throughout Latin America from Mexico as 
far south as Peru and widely naturalized elsewhere. The 
plant has been used both in the traditional medicine and in 
religious rituals with respect to the hallucinogenic 
mushrooms like the peyote [26]. 
 Indeed, the divinatory hallucinogenic properties of these 
three climbing vines are due to psychoactive alkaloids 
exclusively present in the plants seeds. The principal 
psychoactive alkaloids identified in the seeds are ergine 
(lysergamide, lysergic acid amide, LSA) and isoergine, 
compounds able to induce psychoactive effects like those 
from lysergic acid diethylammide (LSD), but with fewer 
intensity [27, 28]. 
 Whereas the seeds of Argyreia nervosa contain about 
0.14% (dry weight) of ergine and 0.19% isoergine alkaloids, 
those of Ipomea violacea 0.2% (dry weight), while Rivea 
corymbosa seeds a percentage of alkaloids between 0.02 and 
0.06% [28-31]. Lysergic acid alkaloids were previously 
isolated only from mushrooms of the Claviceps, Penicillium 
or Rhizopus family [32, 33]. It has been shown that a 2 to 5 
mg dose of ergine is requested for the hallucinogenic action 
[32, 33]. The alkaloid seems to inhibit adenylate cyclase and 
reduce cyclic adenosine monophosphate formation by 
activating the dopamine receptors D2 [34]. LSA has 
psychomimetic effects (mind alterations, hallucinatory 
perceptions and state of awareness) similar but 50-100 times 
less powerful to LSD, that persist for about 4-8 hours. The 
ingestion of seeds could lead to serious psychotic adverse 
effects, like dissociative reactions and schizophrenic 
relapses. The literature has described some cases of toxic 
psychosis characterized by hallucinations, orientation 
problems, anxiety, and psychomotor agitation after the 
ingestion of Argyreia nervosa seeds [35, 36]. 
 A recent study highlighted the variable adverse effects in 
subjects after ingestion of equal doses of Argyreia nervosa 
seeds with interindividually highly differing reactions in type 
and intensity. The study concluded that fluctuating alkaloid 
contents in seeds and multi-drug intoxications make the  
use of this legal high far more dangerous than commonly 
believed [37]. 
Catha edulis: The Psychostimulant Khat 
 Catha edulis is an evergreen shrub cultivated in East 
Africa and in South-West Arabian Peninsula. It is commonly 
called khat, qat or chat [38]. The principal psychoactive 
components of khat are cathinone and cathine. Cathinone,  
((-)-2-aminopropiophenone) is a chemically labile compound 
and in a short time after khat leaves harvesting it is 
transformed to the non-pharmacologically active 3,6-
dimethyl-2,5-diphenylpyrazine. It is for this reason that khat 
needs to be consumed while still fresh. During maturation, 
cathinone is enzymatically converted to cathine (1S, 2S-
norpseudoephedrine), The two substances are chemically and 
pharmacologically related to amphetamines and more in 
general to phenetilamines. In this concern, it’s worth of 
notice to mention that two-thirds of new "designer drugs" 
reported by the Global Drug Survey were represented by 
synthetic cathinones, cathinone structural analogues [2]. 
 Similarly to amphetamine, cathinone-induced psycho- 
stimulation is mediated primarily via the meso-striato–
cortico limbic dopaminergic pathway [39]. Furthermore, 
cathinone was shown to inhibit the re-uptake of epinephrine, 
norepinephrine, and serotonin in animal models [39]. 
However, like in case of domaminergic stimulation, cathinone 
is a threefold less potent than amphetamine in causing 
serotonin release [40]. Although the psychostimulatory 
effects of khat appear to be completely explained by the 
action of cathinone, other plants alkaloids are likely to 
contribute to plant effects. Indeed, at peripheral level cathine 
shows the same simphathomimetic effects as cathinone, even 
if its action on central nervous system appears negligible 
because of its less lipophilic properties [41]. 
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 The recreational effects of khat are commonly obtained 
by chewing the fresh vegetable plant parts (stems, leaves and 
flower buds), although khat can be also ingested as an 
infusion or smoked. Typically, 100–200 g of khat leaves 
wrapped as a bundle in banana leaves are consumed in a 
session, and its effects last for several hours [42]. Khat 
chewing is a traditional habit in eastern Africa and Arabian 
peninsula, but the influx of immigrants from these countries 
has resulted in the importation of khat to countries where 
these immigrants have settled, including Europe and the 
United States [43]. Moreover, several internet websites sell 
and ship fresh khat leaves everywhere [44]. Differently from 
other consumers of psychoactive substances and “legal” or 
“herbal highs”, khat users are unlikely to use other 
psychoactive substances [45]. 
 When chewing khat, cathinone is released producing a 
feeling of euphoria [46]. Cathinone also reduces appetite 
through an unknown mechanism [47]; other effects include 
increased blood pressure associated with a rise in the 
occurrence of vasospasms, acute myocardial infarction, 
unfavorable cardiovascular effects and also problems related 
to the gastrointestinal tract: esophagitis, gastritis [48]. Many 
cases of acute liver failure and many cases of autoimmune 
hepatitis among consumers of Catha edulis have also been 
reported [49]. 
 The fact that in recent decades the traditional habit of 
chewing khat leaves changed towards uncontrolled 
consumption generated a number of reports of psychiatric 
disorders following plant use. Different forms of psychosis, 
hallucination, depression and personality disorders have 
been associated with long-term khat use [50]. 
 In reality, as in case of other psychotropic drugs, khat is 
likely to exacerbate pre-existing psychological disorders, or 
it is used by individuals vulnerable to overcome stress 
caused by the same disorders [50]. The characteristics of 
psychoses following khat use are very similar to those seen 
in chronic amphetamine and cocaine addicts [51]. 
 There have been reports of khat-induced aggressive 
verbal outbursts and violent behaviour in the past, and also a 
recent work describes the presence of disruptive and violent 
behaviour amongst chronic khat users [52, 53]. 
Datura stramonium: The Devil Weed 
 Datura stramonium (aka, Jimson Weed, Angel’s trumpet, 
moon flower, Thorn Apple, Estramonio, Dhaturo, Madak, 
Mad Apple, Trompetilla) is a wild-growing hallucinogenic 
plant belonging to the Solanaceae family [54]. Datura 
stramonium contains a mixture of anticholinergic alkaloids, 
e.g. atropine, hyoscyamine and scopolamine ((-) hyoscine) 
which are the main responsible of its neurotoxic and 
hallucinogenic effects [55]. It widely grows as “gegemu” 
among the Yorubas in the south-western Nigeria, where it is 
mainly used as source of medicines, intoxicants, dyes and 
poison [56]. It is also widely cultivated in Europe, Asia, 
America and South Africa. Traditionally, it has been used for 
mystic and religious purposes and in Ayurvedic medicine as 
an herbal medicine with narcotic effects and to relief 
asthma/bronchitis, flu symptoms, headache, rheumatism, 
haemorrhoid, gout and pain and as sedative in hysterical and 
psychotic patients and in the treatment of insomnia [57]. 
However, as Datura owns a narrow range between the active 
and lethal dose, it has been widely documented its accidental 
poisoning, particularly in contaminated food [58]. 
 Recently, orally and smoked recreationally abuse/misuse 
of Datura leaves or flowers or the seeds has been reported 
by youngsters in search of strong sensations and to 
experience their hallucinogenic effects [59]. Among the most 
commonly reported desired effects, euphoria, surreal 
interactions with world and auditory hallucinations have 
been frequently reported by recreational users. After oral 
intake, the effects may arise in around 20-30 minutes, 
depending on the dose; whilst if smoked, the effects are 
faster (around 5 minutes). After the intake of moderate 
doses, the effects last approximately 8-12 hours; while 
higher doses may also last 2-3 days. 
 Datura seeds and flowers are usually more potent than 
the leaves and roots. Scopolamine and atropine are 
anticholinergic hallucinogens which competitively act by 
inhibiting acetylcholine at muscarinic receptors, which in 
turn excite dopaminergic neurons at the peripheral level of 
the parasympathetic nervous system and at the central 
nervous system level. Parasympaticolytic effects include :1) 
spasmolytic effect (bronchial smooth musculature); 2) 
midriasis and paralysis of the visual accommodation; 3) 
decrease of the secretory activity of the exocrine glands; 4) 
tachycardia; 5) suppression of nausea and vomiting [60]. 
 Several cases of toxicity following voluntary and 
recreationally ingestion of Datura extract were reported, 
particularly among children and teenagers [59, 61, 62]. The 
main clinical effects include anticholinergic delirium, 
restlessness, altered sensorium disorientation and a wide 
range of hallucinations (colloquially defined as Toxidrome: 
“Blind as a bat, mad as a hatter, red as a beet, hot as a hare, 
dry as a bone, the bowel and bladder lose their tone, and the 
heart runs alone”) [54, 62]. At higher doses, it may cause 
incoherent speech, disorientation, delusions, dreamlike 
frenzy, often followed by depression and amnesia; in some 
cases, a sudden surge in strength, energy and subsequent 
aggressive compulsions [59]. Deep coma and convulsions 
may occur as well [62]. Moreover, peripheral nervous system 
symptoms may appear, including mydriasis, dry skin and 
mouth, urinary retention, blurred vision, inability to perspire, 
hyperpyrexia and constipation [54]. 
 Long-term consumption of Datura (around 3 to 4 seeds 
throughout the day with a maximum intake of 6 seeds/day 
over a period of 3 years) resulted in the onset of paranoid 
schizophrenia, an altered state of consciousness and 
aggressive behaviour [63]. Finally, even fatalities related to 
the intake of Datura stramonium were reported, mainly due 
to its accident consumption [64-66]. 
Piper methysticum: The Kava-kava Nature's Legal 
Relaxant 
 Kava-kava (or Sakau or Kawa Kawa, ava root, awa, 
cavain, gea, gi) is the name given to a typical beverage 
prepared with Piper methysticum, a plant belonging to the 
black pepper family, originating from Melanesia and then 
rooted in the Polinesian islands [67]. The roots of the plant 
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are rich of kavain, the principal active ingredient and they 
have been used since at least 3000 years ago in preparing 
kava-kava, that could be considered the “national drink” of 
Polynesia and Melanesia. In the past kava-kava played an 
important role in different religious and political ceremonies, 
and still today it is consumed to restore the physical 
resistance, help sexual performances, acts as an aphrodisiac, 
alleviate stomach pain and many other indispositions. 
 In some western societies, kava-kava is used as a 
prescription-free alternative to the benzodiazepines to relieve 
stress-induced anxiety and insomnia [68]. If taken in little 
doses, kava-kava produces a sensation of wellbeing, 
sharpens the intellectual faculties and makes difficulties 
easier to take. When it is used at medium doses, it acts as a 
muscular relaxant and as spasmolytic producing a quiet and 
pacifying sleep, rich in pleasant dreams. High doses lead a 
deep sleep [69, 70]. 
 The clinical effects of kava-kava are related to a group of 
structurally-related, lipophilic compounds known as 
kavalactones (or kavapyrones), with kavain representing the 
most important one [71, 72]. Numerous proteins including γ-
aminobutyric acid type A receptors (GABAARs), voltage-
gated Na+ and Ca2+ channels, opioid µ and δ receptors, 
dopamine type-2 receptor, histamine type-1 and 2 receptors, 
cannabinoid type-1 receptor, and monoamine oxidase type B 
have been suggested to be the molecular targets for 
kavalactones [71, 73]. Recently, kavain was found to affect 
the expression of TNF-α, an endogenous factor induced by 
inflammatory stimuli although the molecular basis for that 
regulation remains unclear [74, 75]. 
 Facial turgidity, hematuria, macrocitic anaemia, ataxia, 
increased patellar reflexes, weight and hair loss, cutaneous 
eruptions, dyspnea, vision problems, hepatotoxicity, 
gastrointestinal troubles, allergic cutaneous reactions, 
headache, photosensitivity, asthenia, agitation, drowsiness 
and tremors have been associated with chronic consumption 
of Piper mesthycum in high doses [76, 77]. Numerous 
reports of severe hepatotoxicity potentially induced by kava-
kava have also been highlighted, both in the USA and 
Europe [49]. 
 Kava-kava effects can be improved by the assumption of 
other substances acting on the central nervous system, like 
alcohol and certain medicaments, leading to a temporary 
reduction of the cognitive performance or to a partial loss of 
conscience. On the other side, Piper methysticum can 
interact with the metabolism of numerous drugs by inhibiting 
certain isoforms of cytochromes P450, leading to higher risk 
of side effects [78, 79]. Recently it has been described a case 
of suicide due to overdose of kavalactones using intravenous. 
injection together with administration of ethanol [80]. 
Mitragyna speciosa: The Psychedelic Kratom 
 Mitragyna speciosa (Kratom) is an original tree 
belonging to the Rubiaceae family (i.e. coffe plant) of  
South-East Asia, where the plant is used in folk medicine  
as a stimulant (at low doses), sedative (at high doses), 
recreational drug, pain killer, medicine for diarrhea, and 
treatment for opiate addiction drug since ancient times [81]. 
In Thailand, the natives have always used the plant for its 
effects similar to those of opioids and cocaine. Fresh leaves 
from the central rib are usually chewed; dried leaves can be 
chewed (generally after mincing or pulverizing) or smoked; 
both fresh and dried leaves can be boiled for a long time to 
prepare a paste-like compound that can be kept for a long 
time. At present, the dried and pulverized kratom leaves are 
used as legal stimulants or, instead of analgesics for its 
euphoric sedative effects [82-85]. Kratom preparations 
contain over 40 structurally related alkaloids, making their 
pharmacological and toxicological evaluation unique and 
difficult. The main psychoactive components in the leaves 
are the alkaloids mitragynine and 7-hydroxymitragynine 
both found only in Mitragyna speciosa, but other analogues 
have been identified (e.g., speciogynine, paynantheine, and 
speciociliatine) [86]. The effects of Kratom in humans are 
dose-dependent since small doses produce stimulatory 
effects resembling the stimulant effect of drugs such as 
cocaine or amphetamines, while larger dosages tend to be 
associated with sedative-narcotic effects that resemble drugs 
such as opiates [81, 85, 87]. As above reported, mitragynine 
is the principal alkaloid of Mitragyna speciosa. Chemically, 
mitragynine is the 9-methoxy-corynantheidine. The molecule 
is structurally related to both yohimbine (the stimulant 
alkaloid of Pausinystalia yohimbe plant) and to voacangine 
(the alkaloid of Voacanga africana). The molecular structure 
is somewhat similar to psilocibine type or LSD psychedelic 
drugs [88, 89]. 
 It seems that the alkaloids content can change according 
to the geographical area, phases of the plant growth, and year 
seasons [89, 90]. It has been showed that mitragyne acts as 
agonist on the mu (µ), kappa (κ), and delta (δ) opioid 
receptors of the central nervous system, leading to 
depressing effects similar to opioids but with less intensity 
(about 26% compared to morphine); however since its 
structure does not resemble components of the opioid family, 
it has been suggested that mitragyne could present a more 
broad receptor binding activity [91]. Moreover, since 
mitragyne has only weak opiod effects, it has been suggest 
that also 7-hydroxymitragynine contributes to the plant 
properties. This alkaloid is highly potent and presents an 
affinity for the opioid receptors (particularly receptor µ) about 
13 and 46 times higher than morphine and mitragynine, 
respectively [91]. 
 Further studies have revealed how complex is Kratom’s 
pharmacology, involving a κ-opioid and dopamine D1 
receptors interaction in its various effects [92]. Serotonergic 
and adrenergic pathways have also been involved in the 
effects of mitragynine, mostly due to its broad affinity to 
different receptors [93]. Indeed, the pharmacological 
mechanisms responsible for stimulant activity are yet to be 
clearly established. 
 Kratom users report online that at low doses the 
preparation is rather stimulant, mind is “more alert,” with 
increased physical energy and sometimes sexual arousal, and 
they also described “entactogenic” effects, like empathy and 
euphoria. Some people find this sensations anxiogenic rather 
than pleasant. At higher doses, experiences describe it as 
more sedative and analgesic: users prefer to be less sensitive 
to physical or emotional pain, to feel and look calm, and to 
have a general feeling of comfortable pleasure [83]. 
Herbal Highs: Review on Psychoactive Effects and Neuropharmacology Current Neuropharmacology, 2017, Vol. 15, No. 5    755 
 Users reported also a variety of less explored side-
effects; including nausea, constipation, sleep problems, 
temporary erectile dysfunction, itching, and sweating and 
hyperpigmentation and tremor and anorexia and weight loss 
in long term consumption. Some others describe hair loss, 
probably related to a regular (daily) use of Kratom. 
Withdrawal symptoms are also common, including muscle 
aches, irritability, mood disturbances, runny nose, diarrhoea. 
Users describe tolerance (requiring the consumption of 
higher doses to achieve the same effects) and also a “cross-
tolerance” to both kratom and opiates after repeated intake 
[83, 94]. 
 Adverse effects and intoxications cases across various 
countries have also been reported, including liver toxicity, 
seizure, and coma, reports of patients suffering from 
intrahepatic cholestasis after two weeks of kratom use, adult 
respiratory distress syndrome, and hypothyroidism. Evidence 
also suggests that Kratom might be a deadly substance when 
mixed with other compounds [49, 94, 95-98]. 
Hallucinogenic Cacti from Trichocereus Family 
 The Trichocereus family includes about 40 cactecee 
plants. In South America there is an ancient cult tied to 
hallucinogenic cacti such as Trichocereus pachanoi (San 
Pedro), peruvianus, werdermannianus, macrogonus, and 
validus which grow in Perù and in Ecuador, particularly in 
the Andean regions [99]. The historical use is linked to the 
hallucinogenic content of mescaline, a phenethylamine 
structurally different from other major psychedelic drugs 
such as LSD, psilocibine, and DMT [100]. Mescaline is also 
the principal psychedelic alkaloid of another small, spineless 
cactus native to Mexico, Lophophora williamsii or peyote 
[100]. 
 Mescaline acts in the central nervous system by 
stimulating the serotoninergic and dopaminergic receptor 
[101]; the mechanism that underlines cognitive, perceptive 
and affective effects is not still well know; however 
mescaline seems to be able to increased glutamate release at 
the level of the cerebral cortex by acting as a partial agonist 
of the 5-HT2A receptors for serotonine [2]. At the dose of 
350 mg, the first effects of mescaline are observed at about 
30 minutes after the ingestion, and can include nausea, 
vomiting, diarrhea, palpitations, tachycardia, increased blood 
pressure, mydriasis, obscured vision, breathing difficulties. 
Psychomimetic effects, like anxiety, visual and audio 
hallucinations, and alterations of spatial, temporal, sensory, 
tactile perceptions, [102] become noticeable about one hour 
after the intake; moreover the individual can show a strong 
empathy towards static objects or live organisms. The events 
and sensations are usually vividly remembered by the mescaline 
users [103]. 
 Some cases described suicidal tendencies, fear, violent 
behaviours, paranoia, flashback episodes, and effects on the 
skin (i.e. flushing, diaphoresis, and piloerection) [104-108]. 
 In a study on healthy volunteers it has been observed that 
the oral administration of a dose of 500 mg mescaline produced 
about 3-4 hours later an acute psychotic state for about 12-15 
hours [105]. The smallest dose of mescaline which will 
likely produce a psychotic effect has been estimated at 200 
mg given intramuscularly for an average user weight of 80 
kg. A strong toxic effect is observed with approximately 
3.75 mg/kg. The maximum toxic peak occurs within 2-4 
hours post administration and it is resolved within the 
following 4-6 hours [109]. During the first two hours after 
administration, about 87% mescaline absorbed at intestinal 
level is excreted in urine; of this about 55-60% is excreted 
unchanged while 27-30% becomes metabolized to 3,4,5 
trimethoxyphenylacetic acid and 5% is transformed into N-
acetil-(3,4-dimethoxy-5-hydroxy)-phenylethylamine [107]. 
 It has been observed that the association of mescaline and 
other drugs can lead to dependence and tolerance (defined as 
the reduction of the biological response to a constant dose of 
active component) [110]; for example a crossed tolerance 
can be induced by the assumption of mescaline with other 
hallucinogens such as LSD and psilocybin [111]. This 
tolerance can quickly decrease, within a couple of days of 
stopping the drug. 
 Convulsions, coma, rabdomyolisis and renal insufficiency 
have been described when mescaline was taken together with 
alcohol or methadone [112]. Anxiety, depression and 
persistent psychoses have been associated with the long term 
use of mescaline [113]. 
 The use of mescaline is rarely lethal. In human, the toxic 
lethal dose with intramuscular administration is 2.5 mg/kg. 
There are two clinical cases in the literature describing 
fatalities related to the use of mescaline. In the first case the 
death has been caused by a trauma which occurred as a 
consequence of the drug induced delirium. The mescaline 
content in the blood and in the urine of patient were 9.7 
µg/ml and 1163 µg/ml, respectively [114]. In the second case 
of a 32-year-old man, mescaline intoxication produced 
esophageal lacerations (Mallory-Weiss syndrome) with 
blood accumulation and marked pulmonary hemoaspiration 
causing the death). Mescaline plasma and urine concentration 
were 0.48 µg/ml and and 61 µg/ml, respectively. The 
Mallory-Weiss syndrome has been determined probably by 
the profuse vomiting induced by mescaline [115]. 
Salvia divinorum: The Magic Mint for Shamanistic 
Practices 
 Salvia divinorum (Hojas de Maria, Yerba Maria, Hierba 
de la pastora, Ska Maria pastora, Magic Mint, Diviner’s 
sage) is a perennial plant belonging to the Lamiaceae family, 
native to Sierra Mazatec region of Mexico with a long 
history as a divinatory psychedelic compound [116]. It was 
traditionally taken by chewing, drinking or smoking by 
Mazated tribes as a potent hallucinogen. It has been 
remained relatively unknown as entheogen until the mid-
1990s when Siebert [117, 118] firstly documented his self-
experimental intake. It rapidly became easily available 
online where it is currently sold as dried leaves, extracts or 
live plants. It is usually ingested as an infusion, smoked or 
chewed its fresh leaves [119]. 
 The hallucinogenic effect of Salvia divinorum is  
due to Salvinorin A, the principal psychoactive constituent 
of plant leaves [120]. Although Salvinorin A has a 
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pharmacological potency comparable to that of the synthetic 
hallucinogens such as LSD and DOB (4-bromo-2,5-
dimethoxyphenylisopropylamine), the mechanism of action 
is different [121, 122]. In fact, in vivo and in vitro studies 
have showed that Salvinorin A has not any affinity for the 
serotonin 5-HT2A receptors, G-protein-coupled receptors, 
transporters, and ion channels canals that have been 
identified as principal molecular targets of the classic 
hallucinogens (LSD, N, N-dimethyltryptamine, psilocybin, 
mescaline); Salvinorin A is a powerful kappa (k) oppioid 
receptor agonist, whose stimulation seems to be related to 
the psychotropic effects associated with the consumption of 
Salvia divinorum extracts [121]. 
 Salvia divinorum leaves can contain about 0.89 to 3.7 
mg/g of dry weight of active substances, that are enough to 
induce psychoactive effects [123]. 
 In traditional medicine, 4-5 fresh or dried leaves of 
Salvia divinorum have been used like tonic (to combat 
fatigue) and like a panacea, the only true medicine with 
magical properties. An hallucinogenic infusion can be 
obtained using 20-60 fresh leaves [124]. The hallucinations 
are usually visual, auditory and tactile and involve vision of 
two-dimensional surfaces, return to places of the past 
(particularly childhood), sensations of movement (to be 
pulled or twisted by an unknown force), sensations of loss of 
body or of identity, hysterical and uncontrollable laughter 
and distorted perception of reality (sensations of being in 
several places at the same time) [125]. 
 These effects usually appear very quickly (approximately 
within 20-60 seconds after intake) and may last around 5-15 
minutes, if smoked. While the leaves usually induces slower 
onset and longer duration, after oral intake [126]. Some 
clinical data reported long-term effects such déjà vu, 
hallucinogenic persistent perceptual disorder, toxic psychosis 
and other visual disturbances [127]. Neither a physical or 
psychological dependence has been reported for Salvia 
divinorum. Withdrawal effects following discontinuation 
have not been described. Adverse effects include headache, 
mild irritability, throat and lung irritation (when smoked), 
feelings of fear, panic, overly intense experiences, instability 
and increased perspiration [116]. A case of persistent 
psychosis characterized by echolalia (involuntary repetition 
of words or phrases spoken by others), paranoia, agitation 
and conflict of ideas was described in a young man of 21 
years without past mental disorders who had smoked Salvia 
divinorum [128]. 
Tabernanthe iboga: The Psychedelic Sacred Wood 
 Tabernanthe iboga (Black bugbane, le bois sacre, sacred 
wood) is an Apocynaceous shrub Ibogaine, which grows in 
West Central Africa. Its principal psychoactive compound is 
ibogaine, a monoterpene indole hallucinogenic alkaloid 
extracted from the root bark of the plant [129]. 
 Traditionally, it has been ritually used as a medicinal and 
ritual substance during the ceremony of initiation into 
adulthood, in the Bwiti religion [130, 131] Ibogaine was 
firstly isolated and crystallized from Tabernanthe Iboga root 
bark in 1901. In 1939, an Ibogaine-containing extract was 
sold in France as Lambarène, a neuromuscular stimulant for 
the treatment of fatigue, depression and recovery from 
infectious disease. Some Ibogaine-containing products have 
been subsequently marketed, including Bogadin, Iperton, 
Endabuse and Lambargene [131]. During the 1960s, the 
alkaloid was introduced as an anti-addiction agent in the 
detoxification treatment from opiates and craving to alleviate 
abstinence syndrome, craving and to speed up the tolerance 
reversion [132, 133]. 
 Ibogaine is a long-lasting, strong psychedelic, dissociative 
and oneirogen alkaloid. At smaller doses, it is appreciated 
due to its stimulant and aphrodisiac properties [131, 134] 
Common route of administration is oral. The onset of 
symptoms is generally within 45 minutes-3 hours after 
ingestion and may last 24 hours or more. During the phase of 
intoxication, the subject may be immobilized [134]. 
 Ibogaine interacts with multiple receptor sites within 
central nervous system, including the dopaminergic 
(noncompetitively agonist for the DAT), serotonergic 
(noncompetitively agonist for the 5-HT2A), nicotinic, 
GABA and muscarinic receptors as antagonist at N-methyl-
D-aspartate receptors and agonist at the k-opioid receptors 
[134-137]. Ibogaine is metabolized by CYP450 into 
noribogaine (12-hydroxyibogamine), which is more potent 
by acting as a moderate k-opioid receptor antagonist and a 
weak antagonist/partial agonist at µ-opioid receptors [138]. 
 Psychedelic effects usually consist of a ‘triple-phase 
experience’ constituted by a visionary (phase 1), an 
introspection (phase 2) and a residual phase (phase 3). The 
phase 1 appears within 1 to 3 hours of ingestion and lasts 4 
to 8 hours. The predominant reported experiences appear to 
involve a panoramic readout of long-term memory and 
visions or states like a ‘walking dream’ featuring archetypical 
experiences (e.g., transcendent beings, passage along a 
lengthy path or floating). Ibogaine-related visual experiences 
have been more frequently associated with eye closure, 
usually disappearing with eye opening. Phase 2 starts 
approximately 4 to 8 hours after ingestion, with a duration of 
8 to 20 hours. The individuals reported a neutral and reflective 
emotional tone. The attention is usually focused on inner 
subjective experiences. During the residual stimulation 
(phase 3), approximately at 12 to 24 hours after ingestion, 
the intensity of subjective psychoactive experience lessens 
with mild residual subjective arousal/vigilance and the need 
to sleep [139]. 
 Ibogaine untoward effects include ataxia, xerostomia, 
nausea, vomiting, QT-interval prolongation, arrhythmias, and 
cardiac arrest [140-144]. Neither a physical or psychological 
dependence, nor withdrawal effects following ibogaine 
discontinuation have not been described. Several fatalities 
and unexpected sudden cardiac death have been related to 
iIbogaine consumption [140, 142, 145, 146]. The results of 
the preclinical studies and anecdotal reports from addict self-
help groups let hypothesized the use of ibogaine as drug in 
addiction therapy. Unfortunately, this just remain at a 
research level and drug was never introduced in standardized 
protocols of addiction treatments.The mechanism of action 
of ibogaine in the treatment of drug addiction has to be still 
clarified [134]. 
Herbal Highs: Review on Psychoactive Effects and Neuropharmacology Current Neuropharmacology, 2017, Vol. 15, No. 5    757 
CONCLUSION 
 This review demonstrates that even if psychoactive plants 
have been known and used from ancient times, there is still 
limited information regarding subjective and neuro- 
pharmacological effects and consequent eventual toxicity 
when plants are used alone or in combination with 
“classical” drugs of abuse. For this reason, significant safety 
concerns should be raised on recreational use of these 
substances. The majority of the medical literature reporting 
abuse of herbals is anecdotal, and the short- and long-term 
effects of abuse are yet unrecognized. 
 If on the one hand the neuropharmacological effects of 
some of them are well established, on the other, one of the 
most important issue which still needs clarification is the risk 
of addiction due to the abuse of these compounds. For 
certain herbals chronic administration provides evidence for 
an addiction potential with cognitive impairments, which 
suggest its classification as a harmful drug; for some others 
taking into consideration only the recent trends of abuse, 
studies investigating these aspects are lacking. 
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